CRIS – Curis, Inc.
Curis, Inc.CRIS
$0.447Name : Curis, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $17,427,374.00
EPSttm : -0.58
Curis, Inc.
$0.447
4.89%$0.023
CRIS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.87
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.91
EPS Last/This Y
-0.98
EPS This/Next Y
0.37
Price
0.44
Target Price
14
Analyst Recom
1
Performance Q
-55.73
Upside
-9,355.6%
Beta
3.08
Ticker: CRIS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | CRIS | 0.56 | N/A | N/A | 0 |
| 2026-05-12 | CRIS | 0.5492 | N/A | N/A | 0 |
| 2026-05-13 | CRIS | 0.5014 | N/A | N/A | 0 |
| 2026-05-14 | CRIS | 0.5138 | N/A | N/A | 0 |
| 2026-05-15 | CRIS | 0.4905 | N/A | N/A | 0 |
| 2026-05-18 | CRIS | 0.4801 | N/A | N/A | 0 |
| 2026-05-19 | CRIS | 0.4759 | N/A | N/A | 0 |
| 2026-05-20 | CRIS | 0.4936 | N/A | N/A | 0 |
| 2026-05-21 | CRIS | 0.498 | N/A | N/A | 0 |
| 2026-05-22 | CRIS | 0.5011 | N/A | N/A | 0 |
| 2026-05-26 | CRIS | 0.5029 | N/A | N/A | 0 |
| 2026-05-27 | CRIS | 0.5228 | N/A | N/A | 0 |
| 2026-05-28 | CRIS | 0.5237 | N/A | N/A | 0 |
| 2026-05-29 | CRIS | 0.5536 | N/A | N/A | 0 |
| 2026-06-02 | CRIS | 0.505 | N/A | N/A | 0 |
| 2026-06-03 | CRIS | 0.5 | N/A | N/A | 0 |
| 2026-06-04 | CRIS | 0.5 | N/A | N/A | 0 |
| 2026-06-05 | CRIS | 0.47 | N/A | N/A | 0 |
| 2026-06-08 | CRIS | 0.4736 | N/A | N/A | 0 |
| 2026-06-09 | CRIS | 0.443 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | CRIS | 0.56 | 76.8 | -7.3 | -1.15 |
| 2026-05-12 | CRIS | 0.55 | 76.8 | -7.3 | -1.15 |
| 2026-05-13 | CRIS | 0.50 | 76.8 | -6.2 | -1.15 |
| 2026-05-14 | CRIS | 0.51 | 76.8 | -9.7 | -1.15 |
| 2026-05-15 | CRIS | 0.49 | 76.8 | -18.0 | -1.15 |
| 2026-05-18 | CRIS | 0.48 | 76.8 | -18.5 | -1.15 |
| 2026-05-19 | CRIS | 0.48 | 76.8 | -20.0 | -1.15 |
| 2026-05-20 | CRIS | 0.49 | 76.8 | -22.0 | -1.15 |
| 2026-05-21 | CRIS | 0.49 | 76.8 | -17.9 | -1.15 |
| 2026-05-22 | CRIS | 0.50 | 49.0 | -23.3 | -1.56 |
| 2026-05-26 | CRIS | 0.49 | 49.0 | -18.1 | -1.56 |
| 2026-05-27 | CRIS | 0.52 | 49.0 | -25.5 | -1.56 |
| 2026-05-28 | CRIS | 0.52 | 49.0 | -19.4 | -1.56 |
| 2026-05-29 | CRIS | 0.56 | 49.0 | -24.1 | -1.56 |
| 2026-06-01 | CRIS | 0.52 | 49.0 | -15.3 | -1.56 |
| 2026-06-02 | CRIS | 0.50 | 49.0 | -17.8 | -1.56 |
| 2026-06-03 | CRIS | 0.50 | 49.0 | -18.1 | -1.56 |
| 2026-06-04 | CRIS | 0.50 | 49.0 | -18.8 | -1.56 |
| 2026-06-05 | CRIS | 0.47 | 49.0 | -14.4 | -1.56 |
| 2026-06-08 | CRIS | 0.48 | 49.0 | -21.1 | -1.56 |
| 2026-06-09 | CRIS | 0.44 | 49.0 | -11.5 | -1.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | CRIS | 0.70 | 0.57 | 0.69 |
| 2026-05-12 | CRIS | 0.70 | 0.57 | 0.68 |
| 2026-05-13 | CRIS | 0.70 | 0.57 | 0.68 |
| 2026-05-14 | CRIS | 0.70 | 0.57 | 0.68 |
| 2026-05-15 | CRIS | 0.70 | 0.57 | 0.68 |
| 2026-05-18 | CRIS | 0.72 | 0.68 | 0.74 |
| 2026-05-19 | CRIS | 0.28 | 0.68 | 0.74 |
| 2026-05-20 | CRIS | 0.28 | 0.68 | 0.74 |
| 2026-05-21 | CRIS | 0.28 | 0.68 | 0.74 |
| 2026-05-22 | CRIS | 0.28 | 0.68 | 0.74 |
| 2026-05-26 | CRIS | 0.28 | 29.59 | 0.83 |
| 2026-05-27 | CRIS | 0.13 | 29.59 | 0.83 |
| 2026-05-28 | CRIS | 0.13 | 29.59 | 0.87 |
| 2026-05-29 | CRIS | 0.13 | 29.59 | 0.87 |
| 2026-06-02 | CRIS | 0.13 | 29.28 | 0.87 |
| 2026-06-03 | CRIS | 0.13 | 29.28 | 0.87 |
| 2026-06-04 | CRIS | 0.13 | 29.28 | 0.87 |
| 2026-06-05 | CRIS | 0.13 | 29.28 | 0.87 |
| 2026-06-08 | CRIS | 0.13 | 29.28 | 0.87 |
| 2026-06-09 | CRIS | 0.13 | 29.28 | 0.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.25
Avg. EPS Est. Current Quarter
-0.35
Avg. EPS Est. Next Quarter
-0.34
Insider Transactions
0.13
Institutional Transactions
29.28
Beta
3.08
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
43
Growth Score
33
Sentiment Score
25
Actual DrawDown %
99.9
Max Drawdown 5-Year %
-99.8
Target Price
14
P/E
Forward P/E
PEG
P/S
2.47
P/B
1.41
P/Free Cash Flow
EPS
-1.19
Average EPS Est. Cur. Y
-1.56
EPS Next Y. (Est.)
-1.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-299.66
Relative Volume
0.59
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-1.6
EPS 1 30Days Diff
-1.56
EBIT Estimation
-11.5
◆
CRIS
Healthcare
$0.45
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34.5
Range 1M
2.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-172.4%
EPS NY
35.8%
52W%
0.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+3011.1% upside
Upside
+3011.1%
Quality
43
Curis, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 20
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
CRIS
Latest News
—
Caricamento notizie per CRIS…
stock quote shares CRIS – Curis, Inc. Stock Price stock today
news today CRIS – Curis, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRIS – Curis, Inc. yahoo finance google finance
stock history CRIS – Curis, Inc. invest stock market
stock prices CRIS premarket after hours
ticker CRIS fair value insiders trading